நியூரோபைப்ரோமாடோசிஸ் ப்ரோக்ர்யாம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
CHOP and COG Will Validate New Tool to Measure NF1-Related Progressive Vision Loss
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Dr Marco Giovannini honored for neurofibromatosis research
ucla.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ucla.edu Daily Mail and Mail on Sunday newspapers.
New drug reduces tumor volume and pain in patients with neurofibromatosis type 1
Based on preclinical studies of an investigational drug to treat peripheral nerve tumors, researchers at Children s Hospital of Philadelphia (CHOP) as part of the Neurofibromatosis Clinical Trials Consortium have shown that the drug, cabozantinib, reduces tumor volume and pain in patients with the genetic disorder neurofibromatosis type 1 (NF1).
The results of the Phase 2 clinical trial, co-chaired by Michael J. Fisher, MD at CHOP, were published recently in
Nature Medicine. This is the second class of drugs to demonstrate a very promising response rate for NF1 patients with these tumors, said first author Fisher, Chief of the Section of Neuro-Oncology and Director of the Neurofibromatosis Program at CHOP, and Group Chair for the NF Clinical Trials Consortium, which includes 25 sites developing innovative biologically-based clinical trials for complications of NF.